Aster DM QualityQ4 FY26

Aster DM Quality Q4 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹737.95P/E: 122.7Market Cap: ₹64.3K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3
  • QCIL expects continued strong growth momentum in both revenue and margins for the next two years, supported by about 900 additional beds being added in this period.
  • Mature hospitals show steady growth (~13.5-14% revenue growth YoY) with EBITDA expansion driven by complexity enhancement and oncology volume growth.
  • Emerging and focused units report robust ramp-ups: emerging units grew 62.4% YoY in revenue; focused units grew 21% YoY with improved EBITDA margins.
  • Patient volumes are rising with IP volumes up 7-10% yearly and OP footfalls growing similarly, driving revenue increases.
  • Expansion plans include adding beds in Raipur, Bhubaneswar, Banjara, Nagercoil (+100 beds), Nampally (+28 beds), Malakpet, Chattogram, Vizag, and Indore (greenfield).
  • Continued focus on clinical talent attraction and specialty capability upgrades to enhance case mix and ARPOB (average revenue per occupied bed).
  • Growth driven by increasing oncology, cardiology, robotic procedures, and international patient inflows.
  • Payor mix favorably shifting towards cash + insurance segments, supporting higher revenue per patient.

See what Aster DM Quality management said on margin guidance — free account, 30 seconds.

Fundraise plans

- As of FY26, Aster DM Healthcare reported a moderate gross debt of INR 701 crores and a robust liquidity position with cash and cash equivalents of INR 1,327 crores. - The company has planned capital expenditure of INR 2,700 crores over the next 3-4 years to support growth, with INR 350 crores already invested by March 2026. - There is no explicit mention in the transcript of any current or future plans for fundraising through new debt or equity issuance. - The management emphasized maintaining disciplined capital allocation and sustainable profitability, implying cautious and planned capital deployment. - If any fundraising plans arise, the company indicated they would be communicated separately, as seen by their offer to share certain financial details offline. Therefore, based on available information, there is no announced new fundraising through debt or equity at this time.

See what Aster DM Quality management said on order book — free account, 30 seconds.

Capex plans

Yes
  • For FY26, capital expenditure was INR 549 crores, with 45% towards expansion projects.
  • Operationalized:
  • - Whitefield Block D with 159 beds (April 2026).
  • - Aster Ramesh Sanghamitra Ongole brownfield expansion with 75 beds (April 2026).
  • Plans to add ~2,500 beds over the next 4 years at a cost of INR 2,700 crores; INR 350 crores invested till March 2026.
  • QCIL expansion budget is around INR 2,000 crores for 1,700 beds (1,500 brownfield, 200 greenfield).
  • Per bed capex:
  • - Brownfield: INR 0.8-1.1 crores.
  • - Greenfield: INR 1.5-1.6 crores.
  • Focus on sprucing up existing assets, adding clinical capabilities, and enhancing oncology services (e.g., Banjara).
  • Addition of 900 beds planned over next two years.
  • Expansion and capability enhancement in clusters like Raipur, Bhubaneswar, Banjara, Hyderabad, Nagercoil, and Indore.

Track Aster DM Quality — get its next earnings analysis in your feed

How does Aster DM Quality rank vs peers in Healthcare Services?

Pro feature
ThisAster DM Quality
Rev 3Mar 3

How does Aster DM Quality rank in Healthcare Services?

Compare Aster DM Quality against every Healthcare Services company (Q4 FY26) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

Others in Healthcare Services this season

  • Chandan Healthca (Q2 FY27)

    Q2 FY27 operating income: ₹57.94 Cr, up 45.04% YoY from ₹39.95 Cr (Page 8) . Key investor presentation takeaways from Chandan Healthcare Ltd's Q2 FY27 investor

  • Invicta Diagnostic (Q2 FY27)

    Revenue from operations for the half year ended September 30, 2026: ₹379.11 lakhs (Page 4). Key results statement takeaways from Invicta Diagnostic Ltd's Q2 FY2

  • Unihealth Hosp (Q2 FY27)

    1,270 million with a year-on-year (YoY) growth of 6.3% . Key results statement takeaways from Unihealth Hospitals Ltd's Q2 FY27 results statement — and how it r

  • Sangani Hospital (Q2 FY27)

    1008.56 lakhs (~11.8% increase). Key results statement takeaways from Sangani Hospitals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →